Celltrion, Inc. (KOSE:A068270) proposed to acquire Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) on July 29, 2025. Celltrion, Inc. signed an agreement to acquire Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) for $330 million on September 22, 2025. Celltrion, Inc. plans to invest 700 billion won (approximately $503 million) for the acquisition, with the possibility of an additional 300 billion won for small-scale or up to 700 billion won for large-scale expansion, depending on market demand. Celltrion, Inc. will conduct due diligence before deciding on the final agreement and aims to complete the deal within the year if finalized.
The transaction is expected to close by the end of this year.
Celltrion, Inc. (KOSE:A068270) completed the acquisition of Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) on January 2, 2026.
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.4%);
- immunology diseases (9.8%);
- neurology (3.3%): primarily drugs used in treating depression and schizophrenia;
- other (2%).
Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
